Status: Recruiting
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.
Participants needed: 21
Trial details
Phase: Phase 2Age: 18-78Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Sep 8, 2025Locations: 1
Eligibility criteria
≥18 years old [+4]
Patients who have previously received anti-plasma cell therapy, including melpha... [+1]